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Special Article
Effect of brown seaweed on plasma glucose in healthy,
at-risk, and type 2 diabetic individuals: systematic review
and meta-analysis
Kate Vaughan, Viren Ranawana, David Cooper, and Magaly Aceves-Martins
Context: Sustained hyperglycemia triggers chronic disease, including type 2 diabetes.
A considerable volume of research has explored the effects of brown seaweed on
plasma glucose control, but equivocal findings have been reported. Objective: A
systematic review and meta-analysis was conducted to assess the evidence from
human randomized controlled trials (RCTs) on the effects of brown seaweed on
plasma glucose in healthy, at-risk, and individuals with type 2 diabetes. Data
Sources: MEDLINE/PubMed, EMBASE, and the Cochrane Library were searched for
reports published between 2000 and 2020. Data Extraction: Population, interven-
tion, comparator, outcome, and study design data were extracted. Data Analysis:
Eighteen RCTs met our inclusion criteria. The reported results varied across and
between populations. Meta-analyses showed a significant effect, favoring the interven-
tion group for both fasting (mean difference –4.6 [95% CI –7.88, –1.33]) and post-
prandial (mean difference –7.1 [95% CI –7.4, –6.9]) plasma glucose. Conclusion:
Brown seaweed and its extracts show potential for preventing and managing
hyperglycemia. Our meta-analysis confirms that brown seaweed positively affects
plasma glucose homeostasis, with particularly promising postprandial plasma glu-
cose effects. However, further research is needed because no high-quality RCT was
identified. Species-specific and dose–response research is also required.
Systematic Review Registration: PROSPERO registration no. CRD42020187849.
INTRODUCTION
Glucose homeostasis is essential for health, as sustained
hyperglycemia leads to negative consequences such as
islet cell stress, impaired glucose tolerance, and type 2
diabetes (T2DM).1 The global prevalence of diabetes
among adults rose from 108 million in 1980 to 422
million in 2014, and the prevalence is predicted to reach
700 million by 2045.2 T2DM accounts for approxi-
mately 90% of these cases.3
Hyperglycemia and T2DM can be treated with a
combination of dietary modification and exercise.4,5
Treatment at early or pre-diabetic stages (ie, of individ-
uals with elevated plasma glucose levels but who do not
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meet the criteria for diabetes) could reduce the inci-
dence of T2DM.6,7 Dietary approaches are a corner-
stone strategy for controlling plasma glucose.8
A large volume of research has looked at the potential
of marine algae for preventing and managing metabolic
conditions.9 Among these algae are marine seaweeds, a
group of macroscopic multicellular species of 4 major
classes of algae taxonomically classified by color depend-
ing on the pigment they contain. The 4 major classes are
Chlorophyceae (green algae), Cyanophycea (blue-green
algae), Rhodophyceae (red algae) and Phaeophycea
(brown algae).10
Marine algae and seaweeds have long been popular
as food ingredients and medicine, mainly in Asian coun-
tries. Their health benefits have been well documented as
they are a traditional part of the diet. Edible seaweeds are
considered highly nutritious natural foods that provide
few calories while being rich in nonstarch polysaccharides,
proteins, minerals, and vitamins.11 Some of the health
benefits attributed to seaweeds include antidiabetic, anti-
hypertensive, antioxidant and anti-inflammatory effects.12
Brown seaweed accounts for 7 million of the 10 mil-
lion tonnes of seaweed produced each year globally and
comprises over 1800 species.13 Most edible brown sea-
weeds come from the genera Laminaria, Undaria, and
Hizikia.14 Brown seaweeds derive their color from the ca-
rotenoid fucoxanthin in chloroplasts, and these 3 genera
are found primarily in colder waters in the northern
hemisphere. In the initial scoping of the current litera-
ture, it was that evident brown seaweed is the most re-
current seaweed type used in studies of seaweed in the
human diet. Brown seaweeds have been gaining attention
due to their biological compounds, including polysac-
charides (eg, alginate, fucoidan), proteins (eg, phycobili-
proteins), polyphenols (eg, phlorotannins), carotenoids
(eg, fucoxanthin), and n-3 long-chain polyunsaturated
fatty acids (eg, eicosapentaenoic acid).15–19 It has been
suggested that these biological compounds show promis-
ing antidiabetic effects.15,16 Bioactivities reported in the
literature pertain to peptides extracted from brown sea-
weeds such as Undaria pinnatifida (Wakame) and are
reported to exhibit antidiabetic activity via inhibition of
dipeptidyl-peptidase 4.17–19
These suggested antidiabetic properties of brown
seaweeds have been studied in vitro after observational
studies showed a relationship between seaweed
consumption and reduced risk of T2DM.20 While in vitro
studies provide indicative data, they do not predict in vivo
effects, and evidence from randomized controlled trials
(RCTs) in humans is essential for this. The current evidence
for the antidiabetic effects of brown seaweed is equivocal.
The results of human intervention studies have reported
varied findings, so there is a need to synthesize the evi-
dence. This work aims to systematically review the evidence
from human RCTs on the effects of brown seaweed on
plasma glucose in healthy, at-risk, and T2DM individuals.
METHODS
This systematic review protocol was registered in the
International Prospective Register Of Systematic Reviews
(PROSPERO registration number CRD42020187849).
The study followed the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines.21 Moreover, the Population, Intervention,
Comparison, Outcome, Study (PICOS) framework was
used to develop the research question and inclusion cri-
teria and to guide the search strategy (Table 1).
Eligibility criteria
Population: Studies including adults (18 years) reported
as (i) healthy with a Body Mass Index (BMI) of 18.5 and
24.9 kg/m2, (ii) at risk of T2DM (ie, with hyperglycemia
or prediabetes, overweight or obesity [BMI 25 kg/m2]),
or (iii) with T2DM (ie, impaired glucose tolerance, im-
paired fasting glucose, insulin resistance, or impaired in-
sulin sensitivity diagnosed according to standard criteria)
were eligible.
Interventions: Experimental studies investigating the effect of
brown seaweed species and/or their extracts were included.
Comparator: Placebo.
Outcomes: Fasting or postprandial plasma glucose levels.
Study design: Parallel and crossover RCTs were eligible.
Data sources and search strategy
Following an initial scoping review, a sensitive search
strategy was created using a combination of medical
Table 1 PICOS criteria for inclusion of studies
Parameter Criterion
Population Healthy, or at-risk of type 2 diabetes mellitus (ie, with hyperglycemia/prediabetes or overweight/obesity),
or adults (18 years) with type 2 diabetes mellitus
Intervention Brown seaweed and/or brown seaweed species extracts
Comparison Placebo
Outcome Plasma glucose
Study design Randomized controlled trials







































































































subject heading (MeSH) search terms and Boolean
Connectors. The search included brown seaweed, its
most used variants/extracts, and words relevant to the
outcomes and participants (see Appendix 1 in the
Supporting Information online). The literature search
was carried out in May 2020 in the following databases:
MEDLINE, EMBASE, and the Cochrane Central
Register of Controlled Trials. Also, Google Scholar was
searched for additional relevant material. Searches were
restricted to those published in the English language
published between 2000 and 2020.
Study selection and data extraction
Titles, abstracts, and full-text reviews of search results
were screened independently by one reviewer (K.V.),
with a 20% check by a second reviewer (M.A.-M.) to es-
tablish consistency. A standardized electronic data col-
lection form was designed based on the PICOS
framework, and relevant data were extracted from each
included study. One reviewer (K.V.) completed this
process with a 100% check by a second reviewer (M.A.-
M.). Data extracted included study identifiers and study
design. In the case of any disagreement in this process,
a third author was contacted (V.R.).
Quality assessment and risk of bias
The risk of bias was assessed using the Cochrane
Collaboration’s tool for RCTs, which considers 6
domains (ie, selection bias, performance bias, detection
bias, attrition bias, reporting bias, and other bias).22
Overall risk of bias of each publication was categorized
as “low risk”, “high risk”, or “unclear risk”, following
the Cochrane Collaboration tool suggested scores.
Quality was assessed independently by the first author
(K.V.) and a second author (M.A.-M.). In the case of
any disagreement, a third reviewer was consulted
(V.R.).
Synthesis and analysis
A narrative summary of studies that satisfied the inclu-
sion criteria is included in this review, and the main
characteristics were tabulated. Studies that reported suf-
ficient data on plasma glucose outcomes were included
in a meta-analysis. Separate meta-analyses were run for
postprandial plasma glucose (PPG) and fasting plasma
glucose (FPG). Quality assessment and risk of bias were
considered when synthesizing narrative and quantita-
tive results.
The meta-analysis was based on the mean differ-
ence (MD) and standard deviation (SD) of changes
from baseline to follow-up when PPG or FPG was
reported.23,24 Only data for the higher doses were used
whenever more than one dose was given in a study.
When provided, intention-to-treat data were used in
the analyses. Outcomes were included only if quantita-
tive data were reported or derived from graphs using
WebplotDigitizer software.25
Meta-analyses were calculated following the meth-
ods suggested by the Cochrane Review.22 Combined-
design meta-analytic formulae, using the method in
Curtin et al 2002,26 were used to combine parallel and
crossover trial results. Such meta-analyses were under-
taken to determine the treatment effect and statistical
heterogeneity (I2) for the primary outcome measure,
PPG or FPG, each being analyzed separately. A ran-
dom-effects model was used because I2 yielded a per-
centage greater than 85% (implying significant
heterogeneity).23 The analysis was performed using R
statistical software, using the library “metafor”. The
main results are presented in forest plots and described
in the results.
RESULTS
An initial scoping review identified 376 articles, which
helped identify relevant references for refining our
search strategy. Subsequent database searches then
identified 41 articles, and further searches using Google
Scholar identified an additional 3 articles. After remov-
ing duplicates and then title and abstract screening the
search results, 21 full papers were retrieved and assessed
for inclusion. During the assessment, 3 more articles
were excluded (Fig. 1). This review included 18 RCTs,
from which 12 had a crossover design27–38 and 6 had a
parallel design.39–42
Of the 18 studies, 1028,29,32–35 involved an acute in-
tervention as an oral glucose tolerance test (OGTT),
measuring the intervention’s effect on PPG over 2 to
3 h. Five studies27,30,40–42 conducted only long-term
interventions analyzing the effect on FPG. The remain-
ing 339–41 reported on both FPG and PPG. In all the in-
cluded studies, a placebo was used as a control
comparator (Table 2).27–42
The study populations ranged from 12 to 97 partic-
ipants. Ten studies29–38 were conducted on healthy par-
ticipants (n¼ 256) with a normal FPG (<100mg/dL)
and BMI (18.5 and 24.9 kg/m2). A further 6 were car-
ried out on individuals at risk of developing T2DM
(n¼ 357).28,40–44 Yoshinaga and Mitamura (2019)28 and
Lee and Jeon (2015)40 investigated effects on prediabetic
individuals (FPG> 125mg/dL), while Wright et al (2019),42
Hernandez-Corona et al (2014),41 Jensen et al
(2012b),43 and Shin et al (2012)44 investigated effects
on individuals with overweight or obesity (BMI>
25 kg/m2). Only 2 studies, Sakai et al (2019)27 and Kim







































































































et al (2008),39 were conducted on participants with
T2DM (n¼ 48) (Table 2).27–42
Twelve studies27,30–32,34,37,38,40–42,44 investigated
seaweed extracts over whole seaweed, with the most
common extract being sodium alginate (n¼ 6). The
dosage varied between studies (ranging from 0.072 g to
70 g), mainly depending on the intervention provided
(eg, seaweed extract vs whole seaweed). The characteris-
tics of the included studies are described in Table 2.
Evidence for individuals with T2DM
Sakai et al (2019)27 and Kim et al (2008)39 used subjects
with T2DM (FPG 150 to 300mg/dL), but who were oth-
erwise in good health. Kim et al (2008)39 reported that
the daily ingestion of 48 g brown seaweed significantly
lowered FPG and PGB (P< 0.05). In contrast, Sakai
et al (2019)27 investigated the effect of high-molecular-
weight fucoidan and reported no significant effect on
FPG.
Evidence for individuals at risk of T2DM
Lee and Jeon (2015)40 and Yoshinga and Mitamura
(2019)28 reported results from prediabetic individuals,
indicating significant (P< 0.05) lowering of PPG.28,40
Lee and Jeon (2015)40 also investigated effects on FPG
but reported no significant Ecklonia cava dieckol-rich
extract effect. Wright et al (2019),42 Hernandez-Corona
et al (2014),41 Jensen et al (2012b),43 and Shin et al
(2012),44 conducted interventions that analyzed the ef-
fect of various brown seaweed extracts on plasma glu-
cose in individuals with overweight or obesity.
Moreover, they used a number of different doses (rang-
ing from 0.072 g to 22 g) and extract types, including
fucoidan, sodium alginate, and polyphenols. Despite






Additional records identified 
thorough other source
(n=3)





inclusion criteria not met for
 study design (n=1)
 intervention (n=2)
Full-text articles assessed for 
eligibility
(n=21)
Full-text articles excluded (n=3),
inclusion criteria not met for
 year of study (n=1)
 population (n=1)
 outcomes (n=1)
Studies included in narrative 
synthesis
(n=18)
Studies included in quantitative 
synthesis (meta-analysis)
(n=16)
Studies excluded from 
meta-analysis
(n=2)
Figure 1 PRISMA flow diagram.







































































































Table 2 Characteristics of studies included
Study Study design Population Type of brown seaweed Control Outcome (plasma
glucose) measuredCountry Characteristic





















Ulva lactuca (Sea Mustard)
Dose: 48 g
Duration: 4 wk and 2 h






















Duration: 3months and 2 h
Placebo Fasting and postprandial
Shin et al. 201244




















Type: (no name given)
Fucoidan extract
Dose: 0.5 g
Duration: 3months and 2 h
Placebo Fasting and postprandial






















































Dose: 0.5 g and 2.0 g
Duration: 2 h
Cellulose
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Table 2 Continued
Study Study design Population Type of brown seaweed Control Outcome (plasma
glucose) measuredCountry Characteristic













Tanemura et al. 201433
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Type: Undaria pinnatifida (Wakame)
















Dose: 4.06 g, 8.13 g and 8.13 g
Duration: 2 h
Placebo beverage Postprandial



















Type: Laminaria hyperborea and
Lessonia trabeculata
Sodium alginate extract





































Type: (no name given)
Calcium alginate extract
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their differences, none of these studies reported any sig-
nificant effect on plasma glucose levels.
Evidence for healthy individuals
Most studies (n¼ 10) were carried out on healthy adults
with a normal FPG and BMI. These RCTs were cross-
over designs. The study of van den Driessche et al
(2019)30 was the only long-term intervention (17 days)
measuring the effects on FPG. Their results showed that
Undaria pinnatifida (Wakame) had no significant ef-
fect.30 The other 9 studies monitored the effect of
brown seaweeds on PPG in short-term interventions (2
to 3.5 h).29,31–38 Similar to van den Driessche et al
(2019),30 Tanemura et al (2014)33 used the brown sea-
weed Undaria pinnatifida (Wakame) and its sporo-
phylls (Mekabu). The Wakame meal had no significant
effect when compared against a control, whereas the
Mekabu meal significantly lowered PPG (P< 0.05).33
Huang et al (2019),29 El Khoury et al (2014),34
Jensen et al (2012a),35 Williams et al (2004),37 and Wolf
et al (2002)38 investigated the effect of the brown sea-
weed extract sodium alginate on PPG in healthy adults.
Williams et al 2004 analyzed sodium alginate’s effect in
a bar and reported a significant reduction (P< 0.05) in
PPG in healthy adults.37 The other 4 studies used test
beverages as their intervention. Kato et al (2018)32 also
used alginate extract from brown seaweed. However,
since high sodium levels are a risk factor for hyperten-
sion, the calcium salt of alginic acid (calcium alginate)
was used. Results testing both 5% calcium alginate and
8% calcium alginate reported significant (P< 0.05) re-
duction in PPG. Murray et al (2018)31 studied the effect
of brown seaweed (containing 28% polyphenols and
67% fucoidan extract) on healthy adults. Neither low
nor high doses (0.5 g and 2 g) produced a significant ef-
fect on PPG. Like Murray et al (2018)26, Paradis et al
(2011)36 used a blend of brown seaweeds (10% polyphe-
nols, 90% algal polysaccharides). Their results showed
that the 500mg dose had no significant effect in terms
of lowering PPG.
Meta-analysis
Three studies adopted both parallel and crossover
designs and provided both FPG and PPG data. Three
other studies used only a parallel design, and a further 7
studies used only a crossover design. The meta-analysis
of the effects of brown seaweed on FPG and PPG is pre-
sented in Figures 228–31,33,35–41,43,44 and 3.27,39–42
There was a greater reduction in PPG (MD –7.1
[95% CI –7.4, –6.9]) favoring the intervention group, and
this difference was statistically significant (P< 0.001). This
suggests that brown seaweed significantly reduces PPG in
patients with T2DM, those at risk of T2DM, and healthy
individuals. The overall quality of these studies was also
Figure 2 Postprandial plasma glucose outcomes meta-analysis.
Results present the mean difference changes from baseline to follow-up among groups. Overall risk of bias analyzed with the Cochrane
Collaboration’s tool for randomized controlled trials. Abbreviations: 95% CI, 95% confidence interval; C, crossover study design; P, parallel
study design.







































































































rated as unclear for all outcomes evaluated. Heterogeneity
for this pooled estimate was high (I2¼ 99%), likely because
of the variability between interventions (Fig. 2).
There was an overall reduction in FPG (MD –4.6
[95% CI –7.9, –1.3]) favoring the intervention group,
and this difference was statistically significant
(P¼ 0.006), suggesting an effective reduction in the in-
tervention groups compared with the control groups
(Fig. 3). Heterogeneity for this pooled estimate was high
(I2¼ 99%), likely because of the large variability in dos-
ages and intervention characteristics. However, the
overall quality of these studies was rated as unclear for
most outcomes evaluated.
Table 327–42 presents the details of the meta-analy-
ses for crossover, parallel, and combined study designs.
For FPG, both crossover and parallel trials showed an
effect size favoring the intervention. The combined ef-
fect was weighted towards the parallel trials and was sig-
nificant. For PPG, the combined effect was weighted
towards the crossover trials and thus showed an effect
size favoring the intervention, with a tight confidence
interval.
Risk of bias across studies
The risk of bias across all the included studies was vari-
able. However, most of the studies had an unclear risk
of bias (15/18), and 329,32,37 had a high risk of bias. Half
of the studies described the methods used to generate
the allocation sequence in sufficient detail for assessing
whether it should produce comparable groups. Less than
half (7/18) described the methods used to conceal the al-
location sequence in sufficient detail for determining
whether intervention allocations could have been fore-
seen before or during enrolment. Few (4/18) described
all measures used to blind the trial participants and
researchers from knowing which intervention a partici-
pant received. Blinding methods were insufficiently de-
scribed in most studies, and 2 (crossover studies) used
open-label designs. Only Murray et al (2018)31 detailed
measures taken to achieve blind outcome assessment.
Most of the studies (13/18) described the completeness
of the outcome data for each main outcome, including
attrition and exclusions from the analysis, or reported at-
trition and exclusions.
Most of the studies were assessed as unclear or high
(14/18) in another type of bias, since these were either
financed by food or pharmaceutical industries or re-
ceived food supplements from companies. In none of
these studies, the role of the funding or supplement
providers was disclosed or clarified (Table 4).27–42
DISCUSSION
This systematic review of 18 RCTs with a total of 646
participants found mixed reported effectiveness of
brown seaweed on plasma glucose in healthy individu-
als, those at risk of T2DM, and individuals with
Figure 3 Fasting plasma glucose outcomes meta-analysis.
Results present the mean difference changes from baseline to follow-up among groups. Overall risk of bias analyzed with the Cochrane
Collaboration’s tool for randomized controlled trials. Abbreviations: 95% CI, 95% confidence interval; C, crossover study design; P, parallel
study design.







































































































diagnosed T2DM. Our meta-analysis showed promising
effects of brown seaweed over glucose control.
However, the results should be interpreted cautiously,
considering that most evidence had an unclear or high
risk of bias. Furthermore, across the included studies,
the wide range of variables (eg, study design and dura-
tion, type of brown seaweed used, dosage, and other
study-specific variables) might have affected the results.
Studies conducted in vitro45–47 and in diabetic
mice48,49 show that Ascophyllum nodosum (Rockweed)
and Undaria pinnatifida (Wakame) regulate plasma
glucose. However, only 2 of the identified studies have
been conducted in humans with T2DM,27,39 and they
have limited evidence. Our meta-analysis suggests that
brown seaweed has a significant effect on glucose con-
trol. While both studies showed significant effects, they
were not directly comparable, as their only similarity
was their study population.27,39 The latter study (Kim
et al 2008)39 showed the most remarkable success in im-
proving plasma glucose response, with results suggest-
ing that significance may be dose-dependent, as Kim
et al 2008 administered a considerably larger dose (48 g)
in comparison with Sakai et al 2019 (1.62 g).27 Another
important difference between these two studies was the
type of intervention used. Kim et al 200839 opted for
whole brown seaweed rather than a seaweed extract,
supporting in vitro research showing that Laminaria ja-
ponica (Kombu) may have potential in managing
T2DM.50 Further investigations in diabetic individuals
are required in order to clarify the potential of brown
seaweeds for regulating plasma glucose in T2DM.
People with T2DM or those at risk of getting
T2DM often present more than one comorbidity (eg,
obesity).51 In the studies retrieved in our review, not all
of those that evaluated participants with overweight or
obesity showed impaired plasma glucose control.
However, in addition to looking at changes in plasma
glucose, a small amount of weight loss was also reported
in 2 studies,41,44 which might be a confounding factor,
because weight loss is associated with a positive effect
on glycemic control.52 Furthermore, both interventions
included dietary modifications, and that may have af-
fected the overall outcome and could also be a source of
bias.
All studies retrieved were placebo controlled.
However, only one study conducted on participants
with overweight or obesity described in its methods the
type of control measure used. Wright et al (2019)42 used
a placebo filled with microcrystalline cellulose, a com-
mon bulking agent in food production. While there are
contradictory reports on whether microcrystalline cellu-
lose has hypoglycemic effects,53 it serves as insoluble fi-
ber and may influence satiety and energy intake,
influencing weight. In addition, the use of a fiber con-
trol would have helped determine whether any plasma
glucose changes were due to the seaweed polysacchar-
ides specifically or to other biological compounds it
contains.
Murray et al (2018)31 and van den Driessche et al
(2019)30 also used cellulose as their placebo and, similar
to Wright et al (2019),42 reported no significant differ-
ence between the intervention and the placebo.
However, it is important to note that fiber has a lowering
effect on postprandial glycemia54 and could be a poten-
tial reason for the lack of difference between the inter-
vention and the placebo regarding glycemic response.
Studies investigating the effect of brown seaweed
on plasma glucose in individuals with prediabetes
reported a significant lowering of PPG,28,40 with the
suggested mechanism being inhibition of the carbohy-
drate hydrolyzing enzymes a-amylase and a-glucosi-
dase. The studies differed in seaweed species, dosage,
and method of administration. This supports data from
animal research in which Ecklonia cava and Undaria
pinnatifida (Wakame) reportedly decreased PPG levels,
with the same suggested mechanism.55,56
The largest number of studies was carried out on
healthy adults, and these studies provided a robust vol-
ume of data. However, the results were not consistent
throughout the studies because of their considerable
heterogeneity. Very few of these studies, which were
conducted on healthy participants with an average FPG
level and presumably optimal glucose tolerance, showed
a significant effect from the brown seaweed intervention.
There remains an unanswered question on weather the
effectiveness of seaweed might vary according to a estab-
lished glucose tolerance or other metabolic factors, such
as weight.
Table 3 Details of random effects meta-analyses of crossover, parallel, and combined study designs
Outcome Design Pooled effect size Weight Standard error 95% confidence interval
FPG Parallel –4.07 0.33 1.73 –7.46 –0.67
Crossover –11.90 0.02 6.39 –24.42 0.62
Combined –4.60 0.36 1.67 –7.88 –1.33
PPG Parallel 1.50 7.64 0.36 0.79 2.21
Crossover –8.40 52.80 0.14 –8.67 –8.13
Combined –7.15 60.44 0.13 –7.40 –6.90
FPG, fasting plasma glucose; PPG, post-prandial plasma glucose.







































































































Table 4 Risk assessment bias of studies included
















Murray et al. 201831 Low Low Low Low Low Unclear Unclear Unclear
Lee and Jeon 201540 Unclear Unclear Unclear Unclear Low Unclear Low Unclear
Tanemura et al. 201433 Unclear Unclear Unclear Unclear Unclear Unclear Low Unclear
Jensen et al. 2012a35 Low Low Unclear Unclear Low Unclear Unclear Unclear
Wright et al. 201942 Low Unclear Low Unclear Low Low Unclear Unclear
Sakai et al. 201927 Low Unclear Unclear Unclear Low Unclear Unclear Unclear
Huang et al. 201929 Low Low Unclear Unclear Unclear Unclear Unclear High
El Khoury et al. 201434 Low Low High High Low Low Unclear Unclear
Hernandez-Corona et al. 201441 Unclear Unclear Unclear Unclear Unclear Low Unclear Unclear
Williams et al. 200437 Unclear Unclear Unclear Unclear Unclear Low Unclear High
Yoshinaga and Mitamura 201928 Low High High High Low Low Unclear Unclear
Kato et al. 201832 Unclear Unclear Unclear Unclear Low Low Unclear High
Shin et al. 201244 Unclear Low Unclear Unclear High Unclear Unclear Unclear
Wolf et al. 200238 Unclear Unclear Unclear Unclear Low Low Unclear Unclear
Kim et al. 200839 Unclear Unclear Unclear Unclear Low Low Low Unclear
Jensen, et al. 2012b43 Low Low Low Unclear Low Low Unclear Unclear
Paradis et al. 201136 Low Low Unclear Unclear Low Low Unclear Unclear
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This systematic review had some limitations. The
first and most important was the heterogeneity among
studies in terms of study design, type of brown seaweed,
doses, and population characteristics. Also, the small
number of studies made it difficult to determine whether
weight loss significantly affected plasma glucose out-
comes. Furthermore, the available RCTs included parallel
and crossover trials. In most of those with a crossover de-
sign, it was not clear whether the crossover design was
appropriately used, or whether the order of receiving
supplements or foods was correctly assigned or may have
created a potential bias from carry-over effects. Thus,
most of the evidence retrieved had an unclear or high
risk of bias. In addition, the studies were mainly financed
by food or pharmaceutical industries. Thus, the varied
evidence for a beneficial effect of brown seaweed/brown
seaweed extracts could be due to several limitations
across and within this review’s studies. The limitations
identified here should provide guidance in designing fur-
ther studies to improve the quality of the evidence.
The review included studies that used brown seaweed
or extracts of it as their main intervention. The species of
brown seaweed used, the form, and the administration
method varied across studies, which may have influenced
its effectiveness due to variations in composition and struc-
ture. Five of the studies that used brown seaweed species
extract failed to report the source of their extract. Further
limitations included the varying glucose tolerance and insu-
lin resistance between study populations. The participants
in each study population were, therefore, likely to respond
differently depending on the dosage.
To our knowledge, this is the first systematic review
and meta-analysis of RCTs measuring the effect of
brown seaweed on plasma glucose, focusing on human
participants. Seven of the 18 studies included in this re-
view were published in the past 3 years, indicating the
topic’s current relevance. Only RCTs with a placebo as
a comparator were included, which should reduce the
effects due to differences in population characteristics.
Also, synthesizing the available evidence by conducting
a combined meta-analysis that merged parallel and
crossover design studies, following previously defined
statistical methods,26 added strength to our study, help-
ing establish the statistical significance of differences in
results; otherwise, the results of individual studies may
have appeared to conflict with one another. Statistical
significance increases the validity of any observed
results, increasing the reliability of this review.
Current research focuses more on seaweed supplemen-
tation than whole seaweed consumption. The findings to
date provide varied results; therefore, further high-quality
RCTs are required to determine an effective intervention
and dosage method. Future work should explore the pre-
ventative potential of brown seaweed intake, in view of the
time it takes for T2DM to develop. Further research is also
needed on T2DM participants, and on comparing the out-
comes for intervention with seaweed with those for current
pharmacological treatments such as Acarbose.
CONCLUSION
This systematic review and meta-analysis found that
brown seaweed and its extracts possess the potential to
prevent and manage T2DM, either through dietary in-
take or supplementation. In addition, the meta-analysis
confirms that brown seaweed positively affects plasma
glucose homeostasis, with the most promising PPG
effects. However, due to the limited number of studies
and the lack of high-quality studies, there is inadequate
evidence as yet to confirm the seaweed species and dos-
age of most benefit.
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